Advances in pharmacological treatment of schizophrenia

Zhu Zixi, Li Zezhi, Ning Yuping

PDF(975 KB)
PDF(975 KB)
Journal of Chongqing Medical University ›› 2024, Vol. 49 ›› Issue (05) : 625-630. DOI: 10.13406/j.cnki.cyxb.003492
Treatment of mental disorders and functional neurological diseases

Advances in pharmacological treatment of schizophrenia

Author information +
History +

Abstract

Schizophrenia is one of major mental disorders leading to severe mental disabilities，imposing a substantial burden on the society and patients and their families. Advances in science and technology have not only promoted the re-development of traditional medications，but also fostered the emergence of novel drugs like xanomeline-trospium，emraclidine，and trace amine-associated receptor 1，which offer more personalized and effective treatment options. This article delves into the clinical effectiveness and mechanisms of action of these drugs as well as the challenges from the introduction of new medications，such as drug discontinuation，side effects，and the establishment of animal models for drug prediction. Insights into future research directions are provided. We aim to explore the latest progress in schizophrenia medications，offering up-to-date references for researchers and clinicians.

Key words

schizophrenia / novel drug / pharmacotherapy / treatment challenge

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Zhu Zixi , Li Zezhi , Ning Yuping. Advances in pharmacological treatment of schizophrenia. Journal of Chongqing Medical University. 2024, 49(05): 625-630 https://doi.org/10.13406/j.cnki.cyxb.003492

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Marder SR， Cannon TD. Schizophrenia[J]. N Engl J Med，2019，381（18）：1753-1761．
本文引用 [1]
2
Charlson FJ， Ferrari AJ， Santomauro DF，et al. Global epidemiology and burden of schizophrenia：findings from the global burden of disease study 2016[J]. Schizophr Bull，2018，44（6）：1195-1203．
本文引用 [1]
3
Jauhar S， Johnstone M， McKenna PJ. Schizophrenia[J]. Lancet，2022，399（10323）：473-486．
本文引用 [1]
4
Lowe P， Krivoy A， Porffy L，et al. When the drugs don’t work：treatment-resistant schizophrenia，serotonin and serendipity[J]. Ther Adv Psychopharmacol，2018，8（1）：63-70．
本文引用 [1]
5
Hartling L， Abou-Setta AM， Dursun S，et al. Antipsychotics in adults with schizophrenia：comparative effectiveness of first-generation versus second-generation medications：a systematic review and meta-analysis[J]. Ann Intern Med，2012，157（7）：498-511．
本文引用 [1]
6
Shi XJ， Fan FC， Liu H，et al. Traditional Chinese medicine decoction combined with antipsychotic for chronic schizophrenia treatment：a systematic review and meta-analysis[J]. Front Pharmacol，2020，11：616088．
本文引用 [1]
7
Kalinkovich A， Pouyrovsky M， Nasyrova R，et al. Resolution of chronic inflammation as a new adjunctive approach in schizophrenia treatment[J]. Brain Behav Immun，2020，88：867-869．
本文引用 [1]
8
Xu XR， Shao G， Zhang X，et al. The efficacy of nutritional supplements for the adjunctive treatment of schizophrenia in adults：a systematic review and network meta-analysis[J]. Psychiatry Res，2022，311：114500．
本文引用 [1]
9
Ghaderi A， Banafshe HR， Mirhosseini N，et al. Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients[J]. BMC Psychiatry，2019，19（1）：77．
本文引用 [1]
10
Kim S， Kim SW， Bui MAT，et al. SELENBP1 overexpression in the prefrontal cortex underlies negative symptoms of schizophrenia[J]. Proc Natl Acad Sci USA，2022，119（51）：e2203711119．
本文引用 [1]
11
Howes O， Fusar-Poli P， Osugo M. Treating negative symptoms of schizophrenia：current approaches and future perspectives[J]. Br J Psychiatry，2023，223（1）：332-335．
本文引用 [1]
12
Deakin B， Suckling J， Barnes TRE，et al. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis（BeneMin）：a randomised，double-blind，placebo-controlled trial[J]. Lancet Psychiatry，2018，5（11）：885-894．
本文引用 [1]
13
Correll CU， Rubio JM， Inczedy-Farkas G，et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia：systematic overview and quality appraisal of the meta-analytic evidence[J]. JAMA Psychiatry，2017，74（7）：675-684．
本文引用 [1]
14
Koola MM. Antipsychotic-minocycline-acetylcysteine combination for positive，cognitive，and negative symptoms of schizophrenia[J]. Asian J Psychiatr，2019，40：100-102．
本文引用 [1]
15
Romeo B， Willaime L， Rari E，et al. Efficacy of 5-HT2A antagonists on negative symptoms in patients with schizophrenia：a meta-analysis[J]. Psychiatry Res，2023，321：115104．
本文引用 [1]
16
Bugarski-Kirola D， Arango C， Fava M，et al. Pimavanserin for negative symptoms of schizophrenia：results from the ADVANCE phase 2 randomised，placebo-controlled trial in North America and Europe[J]. Lancet Psychiatry，2022，9（1）：46-58．
本文引用 [2]
17
Davidson M， Saoud J， Staner C，et al. Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia[J]. Schizophr Bull，2022，48（3）：609-619．
本文引用 [2]
18
Kaul I， Sawchak S， Correll CU，et al. Efficacy and safety of the muscarinic receptor agonist KarXT（xanomeline-trospium） in schizophrenia（EMERGENT-2） in the USA：results from a randomised，double-blind，placebo-controlled，flexible-dose phase 3 trial[J]. Lancet，2024，403（10422）：160-170．
本文引用 [1]
19
Mullard A. Novel schizophrenia therapy filed for FDA approval[J]. Nat Rev Drug Discov，2023，22（11）：862．
本文引用 [2]
20
Krystal JH， Kane JM， Correll CU，et al. Emraclidine，a novel positive allosteric modulator of cholinergic M4 receptors，for the treatment of schizophrenia：a two-part，randomised，double-blind，placebo-controlled，phase 1b trial[J]. Lancet，2022，400（10369）：2210-2220．
本文引用 [1]
21
Kantrowitz JT. Trace amine-associated receptor 1 as a target for the development of new antipsychotics：current status of research and future directions[J]. CNS Drugs，2021，35（11）：1153-1161．
本文引用 [1]
22
Halff EF， Rutigliano G， Garcia-Hidalgo A，et al. Trace amine-associated receptor 1（TAAR1） agonism as a new treatment strategy for schizophrenia and related disorders[J]. Trends Neurosci，2023，46（1）：60-74．
本文引用 [2]
23
Achtyes ED， Hopkins SC， Dedic N，et al. Ulotaront：review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia[J]. Eur Arch Psychiatry Clin Neurosci，2023，273（7）：1543-1556．
本文引用 [1]
24
Kane JM. A new treatment paradigm：targeting trace amine-associated receptor 1（TAAR1） in schizophrenia[J]. J Clin Psychopharmacol，2022，42（5 Suppl 1）：S1-S13．
本文引用 [1]
25
Pedersen IN， Bonde LO， Hannibal NJ，et al. Music therapy vs. music listening for negative symptoms in schizophrenia：randomized，controlled，Assessor- and patient-blinded trial[J]. Front Psychiatry，2021，12：738810．
本文引用 [1]
26
Baltzersen OB， Meltzer HY， Frokjaer VG，et al. Identification of a serotonin 2A receptor subtype of schizophrenia spectrum disorders with pimavanserin：the sub-sero proof-of-concept trial protocol[J]. Front Pharmacol，2020，11：591．
本文引用 [1]
27
Németh G， Laszlovszky I， Czobor P，et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia：a randomised，double-blind，controlled trial[J]. Lancet，2017，389（10074）：1103-1113．
本文引用 [1]
28
Iyo M， Ishigooka J， Nakamura M，et al. Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia：a 6-week，randomized，double-blind，placebo-controlled study[J]. Psychiatry Clin Neurosci，2021，75（7）：227-235．
本文引用 [1]
29
Frampton JE. Brexpiprazole：a review in schizophrenia[J]. Drugs，2019，79（2）：189-200．
本文引用 [1]
30
Correll CU， Davis RE， Weingart M，et al. Efficacy and safety of lumateperone for treatment of schizophrenia：a randomized clinical trial[J]. JAMA Psychiatry，2020，77（4）：349-358．
本文引用 [1]
31
Fleischhacker WW， Podhorna J， Gröschl M，et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia：a double-blind，randomised，placebo-controlled phase 2 study[J]. Lancet Psychiatry，2021，8（3）：191-201．
本文引用 [1]
32
Anand R， Turolla A， Chinellato G，et al. Phase 2 results indicate evenamide，A selective modulator of glutamate release，is associated with clinically important long-term efficacy when added to an antipsychotic in patients with treatment-resistant schizophrenia[J]. Int J Neuropsychopharmacol，2023，26（8）：523-528．
本文引用 [1]
33
Speyer H， Begemann M， Albert N，et al. Discontinuation of antipsychotic medication-time to rethink trial design[J]. Lancet Psychiatry，2020，7（10）：841-842．
本文引用 [2]
34
Morrato EH. Interpreting evidence on long-acting injectable antipsychotics[J]. Lancet Psychiatry，2021，8（5）：349-351．
本文引用 [1]
35
Yuen JWY， Kim DD， Procyshyn RM，et al. A focused review of the metabolic side-effects of clozapine[J]. Front Endocrinol，2021，12：609240．
本文引用 [1]
36
Goff DC. The pharmacologic treatment of schizophrenia-2021[J]. JAMA，2021，325（2）：175-176．
本文引用 [2]
37
Geyer MA， Olivier B， Joëls M，et al. From antipsychotic to anti-schizophrenia drugs：role of animal models[J]. Trends Pharmacol Sci，2012，33（10）：515-521．
本文引用 [1]
38
Białoń M， Wąsik A. Advantages and limitations of animal schizophrenia models[J]. Int J Mol Sci，2022，23（11）：5968．
本文引用 [1]
39
Dodd S， Carvalho AF， Puri BK，et al. Trace Amine-Associated Receptor 1（TAAR1）：a new drug target for psychiatry?[J]. Neurosci Biobehav Rev，2021，120：537-541．
本文引用 [1]
40
Sotiropoulos MG， Poulogiannopoulou E， Delis F，et al. Innovative screening models for the discovery of new schizophrenia drug therapies：an integrated approach[J]. Expert Opin Drug Discov，2021，16（7）：791-806．
本文引用 [1]

Comments

PDF(975 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉